EMA Authorised: Pluvicto (lutetium (177Lu) vipivotide tetraxetan) — Novartis Europharm Limited

View source ↗

Summary

EU authorization of Pluvicto (lutetium-177Lu vipivotide tetraxetan) for prostatic neoplasms, castration-resistant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms Castration-resistant

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms, Castration-Resistant. MAH: Novartis Europharm Limited. Decision date: 20/07/2026